The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Discovery of 5-[[4-[(2,3-Dimethyl-2 H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor
Open accessAbstract
Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Passaniti, A., Taylor, R. M., Пили, Р., Guo, Y., Long, P., Haney, J. A., Pauly, R. R., Grant, D. S., & Martin, G. R. (1992) · PubMed · Cited by 806
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 749
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M.-C., Hopper, T. M., Miller, C. G., Harrington, L. E., Onori, J. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0193 · Cited by 517
Self-citationSorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233
Self-citationPazopanib: A novel multitargeted tyrosine kinase inhibitor
Sonpavde, G., & Hutson, T. E. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0007-2 · Cited by 203
Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors
Harris, P. A., Cheung, M., Hunter, R., Brown, M. L., Veal, J. M., Nolte, R. T., Wang, L., Liu, W. J., Crosby, R. M., Johnson, J. H., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049538w · Cited by 137
Self-citationA review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis
Baka, S., Clamp, A. R., & Jayson, G. C. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.867 · Cited by 90
Brignola, P. S., Lackey, K. E., Kadwell, S. H., Hoffman, C. R., Horne, E., Carter, H. L., Stuart, J. D., Blackburn, K., Moyer, M. B., Alligood, K. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105907200 · Cited by 77
Dev, I. K., Dornsife, R. E., Hopper, T. M., Onori, J. A., Miller, C. G., Harrington, L. E., Dold, K. M., Mullin, R. J., Johnson, J. H., Crosby, R. M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602109 · Cited by 44
Self-citationInteractions of nitrogen heterocycles with cytochrome P-450 and monooxygenase activity
Murray, M. T., & Wilkinson, C. F. (1984) · Chemico-Biological Interactions · doi:10.1016/0009-2797(84)90036-x · Cited by 25
Bevacizumab in the Treatment of Metastatic Colorectal Cancer
Caprioni, F., & Fornarini, G. (2007) · Future Oncology · doi:10.2217/14796694.3.2.141 · Cited by 23
Role of Bevacizumab for the Treatment of Non-Small-Cell Lung Cancer
Ramalingam, S. S., & Belani, C. P. (2007) · Future Oncology · doi:10.2217/14796694.3.2.131 · Cited by 11
Cited by
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
Recent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Metadata
- Authors
- Harris, P. A., Boloor, A., Cheung, M., Kumar, R., Crosby, R. M., Davis-Ward, R. G., Epperly, A. H., Hinkle, K. W., Hunter, R. N., Johnson, J. H., Knick, V. B., Laudeman, C. P., Luttrell, D. K., Mook, R. A., Nolte, R. T., Rudolph, S. K., Szewczyk, J. R., Truesdale, A. T., Veal, J. M., Wang, L., & Stafford, J. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-07-12
- Volume
- 51
- Issue
- 15
- Pages
- 4632-4640
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2035387891
- Cited by
- 352
- References
- 16
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.